<DOC>
	<DOCNO>NCT01167426</DOCNO>
	<brief_summary>This open-label , multicenter study conduct approximately 20 site . Each patient inject GA daily 6 week utilize autoject 2 device determine overall injection satisfaction .</brief_summary>
	<brief_title>Evaluation Two Glatiramer Acetate ( GA ) Formulations Relapsing-Remitting Multiple Sclerosis ( RRMS ) Patients</brief_title>
	<detailed_description>The study consist 2 week treatment period participant inject current therapy Copaxone 20 mg/1.0 mL glatiramer acetate utilize autoject 2 . All participant roll new formulation 20 mg/0.5 mL glatiramer acetate autoject 2 device 4 week treatment period . Patient satisfaction evaluate use Experience Questionnaire throughout study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Patients â‰¥ 18 year age diagnosis Relapse Remitting Multiple Sclerosis ( RRMS ) Clinically Isolated Syndrome ( CIS ) Currently inject glatiramer acetate 20 mg/1.0 mL per day subcutaneously ( SC ) minimum 90 day utilize autoject 2 glass syringe minimum 75 % daily injection Willing able complete procedure evaluation related study Willing continue follow usual injection site preparation routine adjunctive local injection site reaction ( LISR ) management technique Willing able provide write informed consent Currently use treat another immunomodulating therapy ( IMT ) conjunction GA 30 day prior screen study Currently use investigational drug use treatment investigational agent 30 day prior screen study Pregnant planning pregnancy breastfeed Use parenteral medication ( e.g. , intramuscular , SC , intravenous , etc . ) either currently past 30 day prior screen study Any medical psychiatric condition would make patient unsuitable research , determine Investigator Unwilling perform daily injection autoject 2 device Previous participation study evaluate new 20 mg/0.5 mL formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>Clinically Isolated Syndrome</keyword>
	<keyword>CIS</keyword>
	<keyword>Copaxone</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>Autoject 2</keyword>
</DOC>